LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA

Yuesong Pan, Runqi Wangqin, Hao Li, Aoming Jin, Jiejie Li, Jinxi Lin, Xia Meng, Ying Xian, Daniel T. Laskowitz, Yongjun Wang

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


BACKGROUND AND PURPOSE: Dyslipidaemia is a major risk factor for ischaemic stroke and transient ischaemic attack (TIA). This study aimed to investigate the association between baseline low-density lipoprotein cholesterol (LDL-C) level, lipid-lowering treatment and short-term risk of new stroke in patients with a minor ischaemic stroke or TIA. METHODS: We derived data from the Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events trial. Patients with a minor stroke or TIA were categorised by LDL-C level at baseline (<2.6 or ≥2.6 mmol/L (100 mg/dL)) and with or without lipid-lowering treatment after symptom onset. The primary outcome was a new ischaemic stroke at 3 months. The association of baseline LDL-C level, lowering treatment and outcomes were assessed. RESULTS: Among 3027 patients, 2154 (71.2%) patients had an initial LDL-C ≥2.6 mmol/L, of which 1267 (41.9%) received lipid-lowering treatment. Elevated LDL-C level was associated with a higher risk of new ischaemic stroke at 3 months in patients without lipid-lowering treatment (adj.HR=1.35, 95% CI: 1.19 to 1.53), but not in those with lipid-lowering treatment (adj.HR=0.99, 95% CI: 0.82 to 1.19) (p for interaction=0.007). Patients with LDL-C ≥2.6 mmol/L had a numerically higher risk of ischaemic stroke (11.8% vs 8.0%, adj.HR=1.37, 95% CI: 0.96 to 1.96) in those without lipid-lowering treatment. For patients with LDL-C ≥2.6 mmol/L, lipid-lowering treatment was associated with reduced risk of ischaemic stroke at 3 months (7.9% vs 11.8%; adj.HR=0.54, 95% CI: 0.39 to 0.75). CONCLUSIONS: Elevated untreated baseline LDL-C level was associated with an increased short-term risk of ischaemic stroke among patients presenting with minor ischaemic stroke or TIA. There was potential benefit of lipid-lowering treatment in minor stroke or TIA patients with LDL-C ≥2.6 mmol/L. TRIAL REGISTRATION NUMBER: NCT00979589.

Original languageEnglish (US)
Pages (from-to)276-284
Number of pages9
JournalStroke and Vascular Neurology
Issue number4
StatePublished - Aug 1 2022


  • cerebrovascular disorders
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA'. Together they form a unique fingerprint.

Cite this